CP-45,899, a Beta-Lactamase Inhibitor That Extends the Antibacterial Spectrum of Beta-Lactams: Initial Bacteriological Characterization
A. R. English(Pfizer (United States)), Wayne E. Barth(Pfizer (United States)), John E. Lynch(Pfizer (United States)), Arthur E. Girard(Pfizer (United States)), James A. Retsema(Pfizer (United States))
Cited by 397
Related Papers
Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms
|Antimicrobial Agents and Chemotherapy|1987|461
<b>Molecular cloning and functional analysis of a novel macrolide‐resistance determinant, <i>mefA</i>, from <i>Streptococcus pyogenes</i></b>
|Molecular Microbiology|1996|360
Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution
|Antimicrobial Agents and Chemotherapy|1987|323
Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a-homoerythromycin A derivatives; A new class of macrolide antibiotics, the azalides.
|The Journal of Antibiotics|1988|238
Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection
|Antimicrobial Agents and Chemotherapy|1996|154